Overview

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies
Phase:
Phase 1
Details
Lead Sponsor:
Vincerx Pharma, Inc.